Study ended early – who’s the winner? Zetia or Niaspan?
Could New Jersey lose its pharma edge?
BiogenIdec gets a fast track – Biogen Idec Inc., a Cambridge company known for its multiple sclerosis drugs, said that US Food and Drug Administration has granted it Fast Track designation for a potential treatment of relapsing multiple sclerosis…more
———-
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply